Iovance Biotherapeutics. has been granted a patent for methods to expand tumor infiltrating lymphocytes (TILs) in a closed system, enhancing their efficacy and metabolic health while reducing contamination and costs. The process includes gene-editing and involves multiple expansion steps without opening the system. GlobalData’s report on Iovance Biotherapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Iovance Biotherapeutics, Cytokine activate T-cell based compositions was a key innovation area identified from patents. Iovance Biotherapeutics's grant share as of July 2024 was 20%. Grant share is based on the ratio of number of grants to total number of patents.
Methods for expanding therapeutic tumor infiltrating lymphocytes (tils)
The patent US12031157B2 outlines a method for producing a therapeutic population of tumor infiltrating lymphocytes (TILs) from tumor fragments obtained from a patient. The process involves several key steps: first, tumor fragments are introduced into a closed system to generate an initial population of TILs. This population undergoes a first expansion in a culture medium containing interleukin-2 (IL-2) and optionally OKT-3, lasting approximately 3 to 12 days. The second expansion occurs in a similar medium supplemented with antigen presenting cells (APCs) for an additional 7 to 12 days, resulting in a therapeutic population of TILs. Notably, the transitions between these steps occur without opening the system, ensuring a controlled environment throughout the process. Additionally, gene-editing techniques can be applied at various stages to modify the TILs, particularly to silence or reduce the expression of immune checkpoint genes.
The patent further specifies that the gene-editing can be performed using methods such as CRISPR, TALE, or zinc finger systems, targeting specific immune checkpoint genes like PD-1, CTLA-4, and LAG-3, among others. The claims also allow for the cryopreservation of the harvested therapeutic TILs, enhancing their viability for future therapeutic applications. The detailed methodology aims to improve the efficacy of TILs in cancer treatment by potentially enhancing their ability to combat tumor cells through genetic modifications that reduce inhibitory signals. Overall, this patent presents a comprehensive approach to developing a therapeutic TIL population with enhanced capabilities for cancer immunotherapy.
To know more about GlobalData’s detailed insights on Iovance Biotherapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
